About Jubilant DraxImage

Jubilant DraxImage Inc. (a wholly-owned subsidiary of Jubilant Pharma) is a Nuclear Medicine company that develops, manufactures and commercializes radiopharmaceuticals used for the diagnosis, treatment and monitoring of disease.

Jubilant DraxImage, based in Montreal Canada, has 160 highly skilled employees that provide quality radiopharmaceutical products in 21 different countries around the globe.

Jubilant DraxImage is passionately dedicated to Nuclear Medicine and focused on:
  • Customers: Nuclear Medicine physicians, technologists and radiopharmacists who image and treat their patients in hospitals, imaging centers and radiopharmacies
  • Products: Market leader in North America for I-131 radioiodine therapy (HICON®), Lung perfusion imaging (DRAXIMAGE® MAA) and bone imaging (DRAXIMAGE® MDP/MDP-25)
  • Quality, Sustainability, Dependability:
    • Investment in a portfolio of radiopharmaceutical products and enabling technologies to expand clinical utility of nuclear medicine
    • Focus on supply chain and manufacturing dependability
    • Best in class logistics/distribution
  • People: Recruit, hire and develop highly skilled customer centric employees


About Jubilant Pharma

Jubilant Pharma Limited is a global integrated pharmaceutical company offering a wide range of products and services to our customers across geographies. We organise our business into two segments, namely, Specialty Pharmaceuticals, comprising Radiopharmaceuticals (including Radiopharmacies), Contract Manufacturing of Sterile Injectables and Non-sterile Products and Allergy Therapy Products, and Generics & APIs, comprising Solid Dosage Formulations and Active Pharmaceutical Ingredients.

We supply our products and services to customers in over 85 countries. We have four manufacturing facilities in North America and two in India, coupled with Research and Development centers in North America and India. In addition, we have a distribution network of more than 50 radiopharmacies in the United States.


Specialty Pharmaceuticals



  • Third largest radiopharmaceutical manufacturer in the nuclear medicine industry in the United States based on revenue
  • Second largest centralized commercial radiopharmacy network in the United States with a national footprint of more than 50 radiopharmacies across 22 states


  • One of the global suppliers for several key API products based on market share

Allergy Therapy Products

One of the top three players with a market share of 17.6% in the allergenic extract market in the United States and are currently the sole producer and supplier of venom products for the treatment of allergies in the United States.

Solid Dosage Formulations

One of the market leaders in the United States, based on market share of several key products